9 Meters Biopharma (NMTR) Competitors Add Compare Share Share Competitors Stock AnalysisChartCompetitorsInsider TradesSEC FilingsTrendsBuy This Stock NMTR vs. PRFX, CMND, CANF, JAGX, SONN, ARTL, VIVS, SPRC, ONVO, and ELABShould you be buying 9 Meters Biopharma stock or one of its competitors? The main competitors of 9 Meters Biopharma include PainReform (PRFX), Clearmind Medicine (CMND), Can-Fite BioPharma (CANF), Jaguar Health (JAGX), Sonnet BioTherapeutics (SONN), Artelo Biosciences (ARTL), Organovo (VIVS), SciSparc (SPRC), Organovo (ONVO), and Elevai Labs (ELAB). These companies are all part of the "pharmaceutical products" industry. 9 Meters Biopharma vs. Its Competitors PainReform Clearmind Medicine Can-Fite BioPharma Jaguar Health Sonnet BioTherapeutics Artelo Biosciences Organovo SciSparc Organovo Elevai Labs PainReform (NASDAQ:PRFX) and 9 Meters Biopharma (NASDAQ:NMTR) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, media sentiment, valuation, community ranking, earnings, institutional ownership, analyst recommendations, risk and profitability. Do institutionals and insiders believe in PRFX or NMTR? 37.3% of PainReform shares are owned by institutional investors. Comparatively, 22.3% of 9 Meters Biopharma shares are owned by institutional investors. 34.4% of PainReform shares are owned by company insiders. Comparatively, 2.4% of 9 Meters Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Do analysts recommend PRFX or NMTR? PainReform currently has a consensus price target of $8.00, suggesting a potential upside of 330.11%. Given PainReform's stronger consensus rating and higher possible upside, analysts clearly believe PainReform is more favorable than 9 Meters Biopharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PainReform 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.009 Meters Biopharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has stronger earnings and valuation, PRFX or NMTR? PainReform is trading at a lower price-to-earnings ratio than 9 Meters Biopharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPainReformN/AN/A-$9.34M-$147.33-0.019 Meters BiopharmaN/AN/A-$43.77M-$3.46N/A Which has more volatility & risk, PRFX or NMTR? PainReform has a beta of 0.63, indicating that its share price is 37% less volatile than the S&P 500. Comparatively, 9 Meters Biopharma has a beta of 1.36, indicating that its share price is 36% more volatile than the S&P 500. Does the MarketBeat Community believe in PRFX or NMTR? 9 Meters Biopharma received 34 more outperform votes than PainReform when rated by MarketBeat users. However, 75.00% of users gave PainReform an outperform vote while only 71.15% of users gave 9 Meters Biopharma an outperform vote. CompanyUnderperformOutperformPainReformOutperform Votes375.00% Underperform Votes125.00% 9 Meters BiopharmaOutperform Votes3771.15% Underperform Votes1528.85% Is PRFX or NMTR more profitable? PainReform's return on equity of -450.64% beat 9 Meters Biopharma's return on equity.Company Net Margins Return on Equity Return on Assets PainReformN/A -450.64% -241.33% 9 Meters Biopharma N/A -584.97%-159.45% Does the media favor PRFX or NMTR? In the previous week, PainReform had 1 more articles in the media than 9 Meters Biopharma. MarketBeat recorded 1 mentions for PainReform and 0 mentions for 9 Meters Biopharma. PainReform's average media sentiment score of 1.87 beat 9 Meters Biopharma's score of 0.00 indicating that PainReform is being referred to more favorably in the media. Company Overall Sentiment PainReform Very Positive 9 Meters Biopharma Neutral SummaryPainReform beats 9 Meters Biopharma on 10 of the 14 factors compared between the two stocks. Get 9 Meters Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for NMTR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding NMTR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NMTR vs. The Competition Export to ExcelMetric9 Meters BiopharmaBiotechnology IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.04M$125.03M$5.58B$8.50BDividend YieldN/A3.74%5.28%4.17%P/E Ratio-0.023.2627.1919.64Price / SalesN/A4,109.95408.78152.17Price / CashN/A13.1938.3234.64Price / BookN/A35.896.974.60Net Income-$43.77M-$91.56M$3.23B$248.06M 9 Meters Biopharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NMTR9 Meters BiopharmaN/AN/AN/AN/A$1.04MN/A-0.0220Gap DownPRFXPainReform2.7239 of 5 stars$2.01+2.0%$8.00+298.0%-36.3%$4.05MN/A-0.014Positive NewsCMNDClearmind Medicine1.23 of 5 stars$0.93-2.3%N/A-21.4%$3.96MN/A-0.49N/ANews CoverageEarnings ReportShort Interest ↓Gap DownCANFCan-Fite BioPharma3.1723 of 5 stars$1.11-0.5%$14.00+1,167.0%-65.6%$3.91M$674K-0.628Short Interest ↓Gap UpJAGXJaguar Health2.5662 of 5 stars$3.82+0.4%$60.00+1,472.7%-95.8%$3.89M$11.55M0.0050SONNSonnet BioTherapeutics2.8225 of 5 stars$1.23+0.2%$20.00+1,532.7%-34.1%$3.88M$1M0.0010News CoverageShort Interest ↓ARTLArtelo Biosciences2.1125 of 5 stars$1.11+0.9%$5.50+395.5%-11.2%$3.64MN/A-0.395Analyst DowngradeStock SplitShort Interest ↓Gap DownVIVSOrganovoN/A$1.87+2.7%N/AN/A$3.54M$122K-0.1820Positive NewsGap DownSPRCSciSparc0.9935 of 5 stars$0.33+0.6%N/A-64.2%$3.49M$1.31M0.004Short Interest ↓Gap DownONVOOrganovoN/AN/AN/AN/A$3.47M$122K-2.4020Gap UpELABElevai Labs1.0889 of 5 stars$2.46-6.7%N/A-99.8%$3.46M$2.45M-0.0418Gap Up Related Companies and Tools Related Companies PRFX Alternatives CMND Alternatives CANF Alternatives JAGX Alternatives SONN Alternatives ARTL Alternatives VIVS Alternatives SPRC Alternatives ONVO Alternatives ELAB Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NMTR) was last updated on 6/13/2025 by MarketBeat.com Staff From Our PartnersUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredWhy July 22nd Could Mean Big Changes for Social SecurityIn a stunning move, President Trump has authorized an AI-led transformation of federal agencies, including Soc...Altimetry | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredGold is soaring. Here’s how to get paid from itGold just broke through $3,300… And while the headlines shout about price targets, something even more powe...Investors Alley | SponsoredNew Rule Hits in July — The Smart Money Already MovedA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding 9 Meters Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share 9 Meters Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy NMTR Stock Free NMTR Stock Alerts